65 related articles for article (PubMed ID: 921180)
1. [IgG levels in the sera of melanoma patients (author's transl)].
Daveau M; Pavie-Fischer J; Rivat L; Rivat C; Ropartz C; Peter HH; Cesarini JP; Kourilsky FM
Ann Dermatol Venereol; 1977; 104(6-7):458-60. PubMed ID: 921180
[TBL] [Abstract][Full Text] [Related]
2. [IgG levels in the sera of melanoma patients (author's transl)].
Daveau M; Pavie-Fischer J; Rivat L; Rivat C; Ropartz C; Peter HH; Cesarini JP; Kourilsky FM
Ann Dermatol Venereol; 1977; 104(6-7):458-60. PubMed ID: 900759
[TBL] [Abstract][Full Text] [Related]
3. [IgG subclasses in malignant melanoma].
Daveau M; Pavie-Fischer J; Rivat L; Rivat C; Ropartz C; Peter HH; Cesarini JP; Kourilsky FM
Ann Immunol (Paris); 1977; 128(1-2):113-6. PubMed ID: 848867
[TBL] [Abstract][Full Text] [Related]
4. IgG4 subclass in malignant melanoma.
Daveau M; Pavie-Fischer J; Rivat L; Rivat C; Ropartz C; Peter HH; Cesarini JP; Kourilsky FM
J Natl Cancer Inst; 1977 Feb; 58(2):189-92. PubMed ID: 833869
[TBL] [Abstract][Full Text] [Related]
5. [Urinary evaluation of 5-S-cysteinyldopa and seric evaluation of IgG4 subclass during follow-up of 27 primitive malignant melanomas (author's transl)].
Cesarini JP; Daveau M; Picard F; Fournier E; Rivat L; Rivat C
Ann Dermatol Venereol; 1978 Apr; 105(4):405-8. PubMed ID: 686614
[TBL] [Abstract][Full Text] [Related]
6. [Immune profil in melanoma patients. III. Behavior of immunglobulins (IgG, IgA, IgM) and of whole complement in serum at the beginning and during BCG-therapy (author's transl)].
Knopf B; Wätzig V; Stelzner A
Arch Geschwulstforsch; 1979; 49(4):299-304. PubMed ID: 496567
[TBL] [Abstract][Full Text] [Related]
7. [Secretion of immunoglobulins in malignant melanoma of the skin].
Babakova SV; Kuznetsov VA; Gorodilova VV; Konradov AA; Chervonnaia LV
Vopr Onkol; 1988; 34(3):314-8. PubMed ID: 3358294
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of leukocyte-dependent antibody activity in melanoma patients.
Hersey P; Edwards A; Murray E; McCarthy WH; Milton GW
J Natl Cancer Inst; 1983 Jul; 71(1):45-53. PubMed ID: 6575208
[TBL] [Abstract][Full Text] [Related]
9. Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors.
Litvak DA; Gupta RK; Yee R; Wanek LA; Ye W; Morton DL
J Am Coll Surg; 2004 Jan; 198(1):27-35. PubMed ID: 14698308
[TBL] [Abstract][Full Text] [Related]
10. [Unspecific immunological investigations in patients with malignant melanoma (author's transl)].
Knopf B; Wätzig V
Dermatol Monatsschr; 1982 Jan; 168(1):24-33. PubMed ID: 7044849
[No Abstract] [Full Text] [Related]
11. [Decrease in immunoreactivity in melanoma. Analysis of DNCB tests in the literature].
Remy W; Dorn R; Ulm K; Mayerhausen W
Z Hautkr; 1986 Dec; 61(24):1767-77. PubMed ID: 3825218
[TBL] [Abstract][Full Text] [Related]
12. Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma.
Giacomini P; Veglia F; Cordiali Fei P; Rehle T; Natali PG; Ferrone S
Cancer Res; 1984 Mar; 44(3):1281-7. PubMed ID: 6692408
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary results of immuno-surgical treatment of primary melanoma (author's transl)].
Vanwicjk R; Rustin P; Malek-Mansour S; Castermans-Elias S; Castermans A
Acta Chir Belg; 1975 Jul; 74(4):430-40. PubMed ID: 1146463
[TBL] [Abstract][Full Text] [Related]
14. [Stage I malignant melanoma of the skin. Prognostic value of thickness and level (author's transl)].
Palangié A; Lassau F; Moreau T; Noury-Duperrat G; Cottenot F
Nouv Presse Med; 1981 Jun; 10(28):2337-41. PubMed ID: 7267338
[TBL] [Abstract][Full Text] [Related]
15. Classification and staging of melanoma.
Gershenwald JE; Buzaid AC; Ross MI
Clin Lab Med; 2000 Dec; 20(4):785-815. PubMed ID: 11221515
[TBL] [Abstract][Full Text] [Related]
16. Suppressor cells in melanoma and lung cancer: correlation with the clinical stage.
Minassian AA; Kadagidze ZG
Neoplasma; 1983; 30(2):153-8. PubMed ID: 6221196
[TBL] [Abstract][Full Text] [Related]
17. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
18. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.
Wascher RA; Morton DL; Kuo C; Elashoff RM; Wang HJ; Gerami M; Hoon DS
J Clin Oncol; 2003 Jul; 21(13):2558-63. PubMed ID: 12829676
[TBL] [Abstract][Full Text] [Related]
19. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma.
van Duinen SG; Ruiter DJ; Broecker EB; van der Velde EA; Sorg C; Welvaart K; Ferrone S
Cancer Res; 1988 Feb; 48(4):1019-25. PubMed ID: 3338074
[TBL] [Abstract][Full Text] [Related]
20. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
